AlphAIalphai — Financial news for AI agents
Stock TitanAPR 303 min read$ATHE

ATHE SEC Filings - Alterity Therapeutics Ltd 10-K, 10-Q, 8-K Forms

This page provides access to Alterity Therapeutics Ltd (ATHE) SEC filings, including 10-K, 10-Q, and 8-K forms, as well as insider trading disclosures. As a foreign private issuer, Alterity primarily files 20-F annual reports and 6-K current reports, which often contain crucial updates on clinical trials for ATH434, regulatory statuses, and financial information. The platform also offers AI-powered summaries and sentiment analysis for these filings to assist investors.

Original reporting
Stock Titan
Published Apr 30, 2026, 2:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 30, 2026, 7:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
ATHE SEC Filings - Alterity Therapeutics Ltd 10-K, 10-Q, 8-K Forms — source image
Source · Stock Titan
Decision brief

The 30-second read

$ATHENeutralLow
01

Why it matters

SEC filings provide transparency and updates that can influence investor confidence and stock valuation.

02

Market read

The filings are relevant for investors tracking biotech developments and regulatory progress.

03

What to watch

Potential delays in clinical trials or regulatory approvals not detailed in filings could pose risks.

Timing: long-term

Background

Alterity Therapeutics Ltd is advancing therapies for neurodegenerative diseases, with ATH434 being a key candidate.

Company-level read

Ticker impact

$ATHENeutralMedium confidence
Context

Primary focus of SEC filings, including 20-F and 6-K reports, with updates on clinical trials, regulatory status, and financials.

Expected impact

Potential moderate positive impact if updates are favorable; however, current sentiment remains neutral, suggesting limited immediate price movement.

Evidence & confidence

The filings contain important updates but lack explicit positive or negative signals, leading to a cautious outlook.

Market effects

Sector

Possible influence on biotech and life sciences sectors due to clinical trial updates.

Regional

Limited regional impact; primarily relevant to investors following US and Australian markets.

Global

Moderate, given the company's status as a foreign private issuer and the global interest in biotech innovations.

Counterpoint

What could challenge this read

Favorable updates might be already priced in; unexpected regulatory hurdles could negatively impact stock.

Key entities

  • Company
    Alterity Therapeutics Ltd

    Biotech firm focused on neurodegenerative disease treatments.

  • Drug Candidate
    ATH434

    Lead compound in clinical development for neurodegenerative conditions.

Read at source← All news

Related articles

AUG 12
$ATHEMed

ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) said the USPTO granted a new U.S. composition of matter patent for ATH434, covering a crystalline mesylate form and treatment methods. The patent extends protection to at least 2045 and supports Phase 3 MSA plans by year-end 2026, with potential expansion to Parkinson’s disease.

finanznachrichten.de4 min
JUL 7
$ATHEMedAI 8/10

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

Alterity Therapeutics said FDA end-of-Phase 2 meeting minutes for ATH434 in multiple system atrophy confirm a registrational plan: one pivotal Phase 3 trial plus confirmatory evidence could support approval. The Phase 3 is expected to start by year-end 2026, enrolling ~200 patients randomized 1:1 to ATH434 50 mg vs placebo twice daily for 12 months.

manilatimes.net3 min
JUL 7
$ATHEMedAI 8/10

ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

Alterity Therapeutics said FDA end-of-Phase 2 meeting minutes for ATH434 in multiple system atrophy confirm a registrational plan: one pivotal Phase 3 trial plus confirmatory evidence could support approval. The Phase 3 is expected to enroll ~200 patients, randomized 1:1 to ATH434 50 mg or placebo twice daily for 12 months, with initiation by year-end 2026.

finanznachrichten.de4 min
JUN 9
$ATHEMedAI 8/10

Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder - Alterity

Alterity Therapeutics said the FDA agreed on key elements of the Phase 3 trial design for ATH434, including the study population and dosing regimen, after Phase 2 results showed 48% slowing of disease progression vs placebo. The company expects Phase 3 activities to start by year-end 2026. Alterity also cited April Phase 2 analyses and positive FDA Type C feedback on CMC.

benzinga.com5 min